BioSpace News Archive

PolyBio Research Foundation is excited to announce a new publication in the journal Nature Immunology.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced three new Contract Research Organization CosMxTM Spatial Molecular Imager partnerships.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing and manufacturing niche generic products, announced the appointment of Carter Ward as its Chief Financial Officer, effective September 5, 2023.

Forbion, a leading European life sciences venture capital firm, announces that it has co-led, together with Deep Track Capital, an oversubscribed $175 million Series B financing in Mariana Oncology, the first investment by its Forbion Ventures Fund VI.

Asensus Surgical, Inc. announced a collaboration with NVIDIA to accelerate the development of Asensus’s Intelligent Surgical Unit™ and improve its ability to deliver novel clinical intelligence to surgeons.

Innodem Neurosciences, a leading digital health and AI company, announced today that it has signed a multimillion, multi-year Commercial Framework Agreement with Novartis Pharmaceuticals Canada Inc. (Novartis) to support its continued efforts towards its innovative ETNATM technology (Eye Tracking Neurological Assessment).

With cancer patients top of mind, teams of Bristol Myers Squibb employees will celebrate a decade of Coast 2 Coast 4 Cancer this year and cycle nearly 3,000 miles from Oregon to New Jersey with the goal of raising $1 million in support of the V Foundation for Cancer Research.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Tuesday, September 12 at 10:50 am ET.

Beyond Air, Inc. announced that it has entered into an agreement with Getz Healthcare to commercialize the LungFit PH device in certain countries across the Asia-Pacific region, pending regulatory approvals.

Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its unaudited interim financial results for the six months ended June 30, 2023 and provided an update on recent corporate highlights.